多组件药剂师干预并没有减少门诊患者开始直接服用口服抗凝剂的临床重要药物错误
Alok Kapoor1,2, Parth Patel3, Daniel Mbusa3
1UMass Chan Medical School, Worcester, MA, USA. alok.kapoor@umassmemorial.org.
Journal of general internal medicine
|September 27, 2023
概括
使用DOAC检查清单的临床药剂师干预并没有减少开始或恢复直接口服抗凝剂 (DOAC) 的患者的药物错误. 该研究发现干预组和对照组之间临床重要药物错误 (CIMEs) 没有显著差异.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 患者安全 患者安全
背景情况:
- 直接口服抗凝剂 (DOAC) 是高风险的药物,需要谨慎管理.
- 临床上重要的药物错误 (CIMEs) 是DOAC患者的一个担忧.
- 假设药剂师主导的干预措施可以减少这些错误.
研究的目的:
- 评估临床药剂师在减少CIME方面的多组分干预措施的有效性.
- 评估DOAC检查清单和药剂师随访对患者安全的影响.
主要方法:
- 一个随机对照试验,涉及开始或恢复DOACs的门诊患者.
- 干预包括药剂师评估,咨询,热线访问和使用DOAC检查清单进行监控.
- 对照组接受了标准的护理,并获得了负担能力援助.
主要成果:
- 干预措施没有显著减少抗凝剂相关的CIMEs (IRR 1.17) 或非抗凝剂相关的CIMEs (IRR 1.05).
- 常见的错误包括错过的血液测试和同时使用阿司匹林或NSAIDs的DOACs.
- 尽管有系统的识别,这些错误仍然存在.
结论:
- 临床药剂师使用基于证据的DOAC检查清单进行的多组件干预并没有减少CIME.
- 可能需要进一步的策略来有效地减少与DOAC治疗相关的药物错误.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Pharmacovigilance
876
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
876


